Unconventional dating app Feeld reports surge in ‘vanilla tourists'
Ethical non-monogamy, switch, edging: you might expect these terms to be old hat for people on a non-traditional dating app – but increasingly they're not.
Feeld, which describes itself as being for 'the curious', is being colonised by so-called 'vanilla tourists' – people who are using the app for more conventional dating.
The result is that Feeld has been booming in recent years, at a time when other dating apps' numbers are falling. Since 2022, its user base has grown by 30% year on year, helped by those looking to observe and perhaps dip their toe into experimental lifestyles.
The dating app's chief executive, Ana Kirova, said reaching a wide audience has never been a goal, and she fears alienating longstanding members.
'I do think it's a challenge that it's becoming more mainstream in some ways,' she said. 'How do we welcome people who've never heard of Feeld, who don't understand the list of sexualities and genders[or] who don't understand what ethical non-monogamy is?'
But she added: 'Every time someone tells me about this vanilla people being on the app, I just ask: 'What's the problem with vanilla?' Why are we so binary about it? There is vanilla, which is boring and whatever, and then there is the rest, which is dark and interesting.
'We don't yuck anyone's yum … and that does count for more traditional relationships and popular sexual experiences, too. I think there is space for that.'
Unlike other dating apps, users are able to browse profiles without gamified swiping 'like' and 'dislike', and Feeld does not use AI or predictive algorithms to find matches, which Kirova likens to 'shopping for granola'.
'That constrains the experience for the members. As soon as you join the app, you're put on to a conveyor of what your experience should be. And the platform makes a lot of choices for you in order for an algorithm to match you and people, because there is a default assumption for everyone that you're there to find X,' she added.
As a result, she believes there is less – although not no – bad behaviour such as ghosting and 'benching' someone in the belief there is someone better a swipe away.
However, she added that safety is still a battle. 'With toxic misogyny still a challenge in wider society, it inevitably finds its way into the dating app landscape,' she said.
There has also been a proliferation of sophisticated romance scams, for which Feeld uses AI to identify fake profiles. 'There are big companies that are investing in scammers. It's like there is Feeld and then there is the 'dark Feeld' somewhere, with a lot of people and resources invested into making fake accounts on dating apps … it's a real difficult thing to tackle,' she said.
Feeld has benefited from changing cultural attitudes towards sex, relationships, sexuality and identity, and a shift away from the 'linear journey from single to coupled to married to having children to having a house', Kirova says.
She has observed a growing openness. 'Older generations look at identity and sexual orientation as quite static. They're starting to change slowly, but that's their perception. Whereas younger people see them as ongoing, growing and changing parts of the self.'
Kirova said the app's second fastest growing demographic is women over 40, with numbers rising by 16% last year, thanks to culture and media challenging 'silly and offensive' perceptions of older women's sexuality.
Feeld has also managed to hold on to gen Z users, who are turning away from other dating apps. 'There is also space for people finding friends and space for people finding community. I think especially gen Z are not always looking for sex on the app,' she said. For the curious: ethical non-monogamy involves having multiple relationships in a fully consensual away, a switch is someone happy to take on either a dominant or submissive role in BDSM, and edging involves delaying orgasm by giving or taking away pleasure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Tyrant
29 minutes ago
- Geek Tyrant
Danny Boyle Explains 28 YEARS LATER Is the "Opposite" of What You'd Expect from a Zombie Sequel — GeekTyrant
If you're expecting 28 Years Later to go big in the way most sequels do with more infected, more explosions, global stakes, director Danny Boyle has a curveball for you. The long-awaited follow-up to his game-changing 2002 film 28 Days Later isn't trying to outdo the apocalypse. It's trying to understand what's left after it. Speaking to IGN, Boyle revealed that he and writer Alex Garland initially flirted with the typical sequel playbook. 'In fact, Alex wrote one script at one point, but they were kind of what you'd expect, and by that I mean things that you expect from a sequel, like the virus is weaponized by a military or a government or a shady [organization]... That kind of thing. And neither of us were very taken by it.' Instead of following the infection across continents in a World War Z -style expansion, Boyle and Garland made a sharp U-turn. They chose to pull the focus inward. 'We began to discuss this idea of doing a much bigger project, which was a series of films that sort of did the opposite of spreading it to Europe and the world.' This reflective approach lines up with what Boyle believes horror can do best by holding up a mirror. 'We turned back and looked at ourselves and we thought … it was very much like an England [type] film. So we kind of narrowed it down. We did the opposite of what you'd expect and it was because we had a lot to think about.' That "thinking" touches on the real-world fractures that have emerged in the years since 28 Days Later first hit theaters. Boyle mentions Brexit and the UK's shifting identity, hinting that this new chapter won't just be about rage-infected hordes, but about how a nation processes trauma. 'That's what you use these films for. They're not lectures or anything like that, but they do reflect, or there is a reflection in them, of where you are and what's happened to you really as individuals and as people." The sequel stars Jodie Comer, Aaron Taylor-Johnson, and Ralph Fiennes, and centers on a group of survivors who've been living in relative isolation on a remote island. When they return to the mainland, they're confronted not just with the infected, but with the haunting question of what's changed, and what hasn't. If 28 Days Later redefined what a zombie film could be in the early 2000s, 28 Years Later is looking to flip the genre on its head once again, this time with an eerie calm and a deeper question at its core. 28 Years Later opens in theaters June 20, 2025.
Medscape
an hour ago
- Medscape
Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday. In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (NAION). But this is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. NAION is the second-most common cause of blindness due to optic nerve damage, after glaucoma. "This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns," said Barclays analyst Emily Field. U.S.-listed shares of the Danish drugmaker were up nearly 2.5% in early trading. The EMA, which started its review in December, has asked Novo to add NAION as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The "benefit-risk profile of semaglutide remains favorable," the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust CEO Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about $150 billion by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing NAION by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing NAION more than doubled after two years of treatment with Ozempic, compared to patients taking medicines from other classes. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. (Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Medscape
an hour ago
- Medscape
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial. Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects. 'Safety's been a key consideration with these drugs,' study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News . Sibeprenlimab represents a new mechanism of action and 'we don't yet fully understand the profile, so we've been looking at that data very carefully,' explained Perkovic. 'In particular, the infection risk has been my biggest concern, given we know that infections are dramatically increased in people with steroid therapy for example, in IgA nephropathy.' The results of the trial — the largest to date in the field — were presented at the 62nd European Renal Association Congress 2025 on June 6 and drew a warm applause from the audience. An Underestimated Condition IgA nephropathy is estimated to affect 2.5 per 100,000 people per year, although 'it's possible that that number is a significant underestimate,' said Perkovic. Diagnosis typically occurs between 20 and 40 years of age. And, despite supportive care, the majority of patients have a high lifetime risk of end-stage kidney disease (ESKD), with up to 50% of patients progressing to ESKD within 20 years of their clinical presentation. 'It's quite likely we've underestimated just how important this condition is,' said Perkovic, but 'we're fortunate that we're in the middle of something of a golden age of developing new treatments.' A number of therapies have been shown to reduce the risks associated with the disease, although they do not necessarily address the immunological basis of the condition. In addition to newer treatments, 'corticosteroids have long been used for people with IgA nephropathy,' Perkovic said, 'but of course, corticosteroids also have a range of different effects across the immune system,' which can lead to adverse outcomes. Sibeprenlimab is a selective IgG2 antibody that binds to and inhibits the biological activity of APRIL (a proliferation-inducing ligand), which is produced by mucosal epithelial and myeloid cells and binds to B cells. APRIL regulates B-cell-mediated immune responses and mediates IgG and IgA class switching in mature B cells. It is these two actions that make APRIL a key factor in the so-called 4-Hit process in the pathogenesis of IgA nephropathy, which results in the deposition of immune complexes in the glomerulus, leading to proteinuria and loss of kidney function. Phase 3 VISIONARY TRIAL Following on from the successful phase 2 ENVISION trial of sibeprenlimab, the researchers undertook the phase 3 VISIONARY trial, an ongoing study involving patients with biopsy-confirmed IgA nephropathy from 240 sites in 31 countries, who were randomized to sibeprenlimab or placebo for 100 weeks and followed up for a further 12 weeks. All patients were required to have a uPCR of ≥ 0.75 g/g or urine protein excretion of ≥ 1.0 g/day, an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2, and to have been on a stable dose of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a SGLT2 inhibitor, for ≥ 3 months prior to screening. For the current pre-specified interim analysis, Perkovic reported the efficacy and safety results in the first 320 randomized patients (152 in the sibeprenlimab group and 168 in the placebo group), focusing on the primary endpoint of 24-hour uPCR at 9 months vs baseline, with eGFR and other data expected to be presented in 2026. The median age of the patients was 42-43 years. There were proportionally fewer females in the sibeprenlimab group (34.2%) vs the placebo group (40.5%). The majority of the patients were Asian, at 61.8% and 56.5%, respectively. Compared with a rise in uPCR at the 9-month follow-up in the placebo group, sibeprenlimab was associated with a 50.2% reduction in uPCR, giving a highly significant placebo-adjusted treatment effect of 51.2% ( P < .0001). Importantly, the benefit of sibeprenlimab on uPCR was seen as early as 4 weeks after initiating treatment and continued to accrue throughout follow-up. Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, who co-chaired the session, told Medscape Medical News that the results look 'very promising.' 'Recently, we have had several agents working in different ways that all show proteinuria lowering,' he continued, but the results from those studies show that the improvements seen in VISIONARY are 'the best proteinuria lowering' seen so far. Gansevoort noted, however, that this remains an interim analysis, and that he is really looking forward to seeing the kidney function results, adding: 'It was a little bit of a pity that they were not allowed to show at least the 9-month interim data on kidney function, which would have been so interesting.' Safety Results In terms of safety, the proportion of patients experiencing a treatment-related treatment-emergent adverse event (TEAE) was marginally lower with sibeprenlimab, at 32.9% vs 31.0% with placebo. The proportion of patients having a TEAE that led to treatment discontinuation was 0.7% vs 2.4%, respectively, and there were fewer severe and serious TEAEs with the experimental drug. 'If we focus on the infection-related adverse events,' Perkovic said, 'we can see that rates were numerically slightly higher in the sibeprenlimab than the placebo group, with a pattern that was broadly consistent, but with perhaps a slight excess of COVID 19.' He noted that this was 'the reverse of the pattern we've seen in the phase 2 trials, suggesting a chance' outcome. 'The data so far look remarkably encouraging,' he added. There's really no suggestion of an increased risk of infection,' with no opportunistic infections identified, 'and certainly no deaths.' More data is required from the ongoing follow-up to support what has been observed so far, but if the final results do bear out both the efficacy and safety outcome, it will show that sibeprenlimab is 'a precision approach to the fundamental abnormality in IgA nephropathy: that's the really exciting part,' said Perkovic. The study was funded by Otsuka Pharmaceutical Development and Commercialization. Perkovic declares relationships with Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chinook Therapeutics, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Guard Therapeutics, Incyte, Janssen, Merck, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Shaanxi Micot Technology, Travere Therapeutics.
